The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease
Abstract
BACKGROUND: The prevalence of pulmonary hypertension in adults with sickle cell disease, the mechanism of its development, and its prospective prognostic significance are unknown. METHODS: We performed Doppler echocardiographic assessments of pulmonary-artery systolic pressure in 195 consecutive patients (82 men and 113 women; mean [+/-SD] age, 36+/-12 years). Pulmonary hypertension was prospectively defined as a tricuspid regurgitant jet velocity of at least 2.5 m per second. Patients were followed for a mean of 18 months, and data were censored at the time of death or loss to follow-up. RESULTS: Doppler-defined pulmonary hypertension occurred in 32 percent of patients. Multiple logistic-regression analysis, with the use of the dichotomous variable of a tricuspid regurgitant jet velocity of less than 2.5 m per second or 2.5 m per second or more, identified a self-reported history of cardiovascular or renal complications, increased systolic blood pressure, high lactate dehydrogenase levels (a marker of hemolysis), high levels of alkaline phosphatase, and low transferrin levels as significant independent correlates of pulmonary hypertension. The fetal hemoglobin level, white-cell count, and platelet count and the use of hydroxyurea therapy were unrelated to pulmonary hypertension. A tricuspid regurgitant jet velocity of at least 2.5 m per second, as compared with a velocity of less than 2.5 m per second, was strongly associated with an increased risk of death (rate ratio, 10.1; 95 percent confidence interval, 2.2 to 47.0; P<0.001) and remained so after adjustment for other possible risk factors in a proportional-hazards regression model. CONCLUSIONS: Pulmonary hypertension, diagnosed by Doppler echocardiography, is common in adults with sickle cell disease. It appears to be a complication of chronic hemolysis, is resistant to hydroxyurea therapy, and confers a high risk of death. Therapeutic trials targeting this population of patients are indicated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with higher rates of hemolysis have lower steady-state Hb levels and are more likely to develop vascular injury and organ dysfunction as they age, manifesting as pulmonary hypertension, diastolic left heart disease, and renal dysfunction (proteinuria, albuminuria, and chronic kidney dysfunction) (62, 64, 65, 70, 79).”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [64]
Citations
Cites
Recommendations for Quantitation of the Left Ventricle by Two-Dimensional Echocardiography
Schiller, N. B., Shah, P. M., Crawford, M., DeMaria, A., Devereux, R., Feigenbaum, H., Gutgesell, H., Reichek, N., Sahn, D., Schnittger, I., et al. (1989) · Journal of the American Society of Echocardiography · doi:10.1016/s0894-7317(89)80014-8 · Cited by 8,121
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320
Self-citationQuiñones, M. A., Otto, C. M., Stoddard, M., Waggoner, A., & Zoghbi, W. A. (2002) · Journal of the American Society of Echocardiography · doi:10.1067/mje.2002.120202 · Cited by 2,130
Adams, R. J., McKie, V. C., Hsu, L., Files, B., Vichinsky, E., Pegelow, C., Abboud, M., Gallagher, D., Kutlar, A., Nichols, F. T., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807023390102 · Cited by 1,866
De Caterina, R., Libby, P., Peng, H. B., Thannickal, V. J., Rajavashisth, T. B., Gimbrone, M. A., Shin, W. S., & Liao, J. K. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118074 · Cited by 1,782
Primary Pulmonary Hypertension
Rubin, L. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701093360207 · Cited by 1,726
Cerebrovascular accidents in sickle cell disease: rates and risk factors.
(1998) · PubMed · doi:10.1182/blood.v91.1.288 · Cited by 1,694
Dams, R. O. J. A., Ie, V. I. C. M. C. K., Su, L. E. H., Iles, B. E. F., Ichinsky, E. L. V., Egelow, C. H. P., Bboud, M. I. A., Allagher, D. I. G., Utlar, K., Ichols, F. E. T. N., et al. (2015) · Cited by 1,338
Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease
Reiter, C. D., Wang, X., Tanus-Santos, J. E., Hogg, N., Cannon, R. O., Schechter, A. N., & Gladwin, M. T. (2002) · Nature Medicine · doi:10.1038/nm1202-799 · Cited by 1,330
Self-citationCell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease
Reiter, C. D., Wang, X., Tanus-Santos, J. E., et al. (2002) · Nature Medicine · doi:10.1038/nm799 · Cited by 1,097
Cited by
Updated clinical classification of pulmonary hypertension
Simonneau, G., Gatzoulis, M. A., Adatia, I., Celermajer, D., Denton, C., Ghofrani, A., Gomez Sanchez, M. A., Krishna Kumar, R., Landzberg, M., Machado, R. F., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.029 · Cited by 4,191
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Humbert, M., Kovacs, G., Hoeper, M. M., Badagliacca, R., Berger, R. M. F., Brida, M., Carlsen, J., Coats, A. J. S., Escribano-Subias, P., Ferrari, P., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac237 · Cited by 3,975
Authors/Task Force Members, Galie, N., Hoeper, M. M., Humbert, M., Torbicki, A., Vachiery, J.-L., Barbera, J. A., Beghetti, M., Corris, P., Gaine, S., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp297 · Cited by 3,846
Haemodynamic definitions and updated clinical classification of pulmonary hypertension
Simonneau, G., Montani, D., Celermajer, D. S., Denton, C. P., Gatzoulis, M. A., Krowka, M., Williams, P. G., & Souza, R. (2019) · European Respiratory Journal · doi:10.1183/13993003.01913-2018 · Cited by 3,813
Rees, D. C., Williams, T. N., & Gladwin, M. T. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61029-x · Cited by 2,504
Self-citation
Metadata
- Authors
- Gladwin, M. T., Sachdev, V., Jison, M. L., Shizukuda, Y., Plehn, J. F., Minter, K., Brown, B., Coles, W. A., Nichols, J. S., Ernst, I., Hunter, L. A., Blackwelder, W. C., Schechter, A. N., Rodgers, G. P., Castro, O., & Ognibene, F. P.
- Affiliations
- National Institutes of Health (US)
- National Heart, Lung, and Blood Institute (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-02-26
- Volume
- 350
- Issue
- 9
- Pages
- 886-895
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2148547093
- Cited by
- 1,325
- References
- 42
- Citations by year
- 2026: 42 · 2025: 30 · 2024: 45 · 2023: 44 · 2022: 42 · 2021: 47 · 2020: 34 · 2019: 61 · 2018: 43 · 2017: 57 · 2016: 74 · 2015: 64 · 2014: 76 · 2013: 64 · 2012: 68
- FWCI
- 35.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Digital Howard (Howard University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Keywords
- pulmonary hypertension, sickle cell disease, mortality risk, tricuspid regurgitation velocity, Doppler echocardiography, chronic hemolysis, hydroxyurea therapy, risk factors, alkaline phosphatase, lactate dehydrogenase, transferrin, cardiovascular complications, renal complications
- MeSH terms
- Adult, Anemia, Sickle Cell, Antisickling Agents, Blood Pressure, Cause of Death, Drug Resistance, Female, Hemolysis, Humans, Hydroxyurea, Hypertension, Pulmonary, Male, Pulmonary Artery, Risk Factors, Tricuspid Valve Insufficiency, Echocardiography, Doppler, Prevalence, Survival Rate, Logistic Models, Ventricular Function
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease. https://app.cochat.ai/papers/10.1056/nejmoa035477
- The paper
- Gladwin, M. T., Sachdev, V., Jison, M. L., Shizukuda, Y., Plehn, J. F., Minter, K., Brown, B., Coles, W. A., Nichols, J. S., Ernst, I., Hunter, L. A., Blackwelder, W. C., Schechter, A. N., Rodgers, G. P., Castro, O., & Ognibene, F. P. (2004). Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease. New England Journal of Medicine. https://doi.org/10.1056/nejmoa035477
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.